Active - Last updated on: December 02, 2024

AstraZeneca ADRHedged Securities is designed to give investors exposure to the AstraZeneca ADR with the added benefit of an embedded currency hedge. The currency hedge is designed to help mitigate the volatility between the GBP and the U.S.Dollar.

AstraZeneca is a UK-listed biopharmaceutical company focused on three main disease areas: Oncology, BioPharmaceuticals and Rare Disease. AstraZeneca has a robust, industry leading pipeline across areas including oncology, cardiovascular, renal & metabolism, respiratory & immunology, vaccines & immune therapies, and rare diseases.

Investment Objective

The AstraZeneca PLC ADRhedged™ (the “Series”) seeks to provide investment results that correspond generally, before fees and expenses, to the total return of the ordinary shares of AstraZeneca PLC in its local market

Underlying Security Details

Fund Inception 10/01/2024
Expense Ratio 0.19%
CUSIP 74016W304
Total Assets $1,805,558.30

Trading Information as of 12/02/2024

Symbol AZNH
Lead Market Maker Citadel
NAV Symbol AZNH.NV
Shares Out. Symbol AZNH.SO

Net Asset Value1 as of 12/02/2024

NAV $45.14
Change $-0.09
Change % -0.20%
Premium/Discount to NAV -0.16%

Closing Market Price2 as of 12/02/2024

Closing Market Price $45.07
Change $-0.13
Change % -0.29%

Fund Performance as of 12/02/2024

Total Return Since Inception
At NAV $—
At Market Price $—

Returns are average annualized total returns, except those for periods of less than one year, which are cumulative.

The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. Market price returns are based upon the closing composite market price and do not represent the returns you would receive if you traded shares at other times.

Fund Holdings as of 12/02/2024

Ticker Name Shares Market Value % of Net Assets
AZN AstraZeneca plc 24,653.00 $1,652,737.12 92.07%
Cash $142,442.67 7.93%

Fund holdings and allocations are subject to change at any time.

1. Net Asset Value (NAV): The dollar value of a single share, based on the value of the underlying assets of the fund minus its liabilities, divided by the number of shares outstanding. Calculated at the end of each business day.

2. Market Price: The current price at which shares are bought and sold. Market returns are based upon the last trade price.

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the Fund, please call (844) 954-5333 or visit our website at www.adrhedged.com. Read the prospectus or summary prospectus carefully before investing.

As with any investment, you could lose all or part of your investment in the Series, and the Series performance could trail that of other investments.

Market Risk. The prices of the securities in the Series are subject to the risk associated with investing in the stock market, including sudden and unpredictable drops in value. An investment in the Series may lose money.

Currency Hedging Risk. Because changes in foreign currency exchange rates affect the value of ADRs, the Series enters into the Currency Hedge Contract in order to seek to minimize the impact of fluctuations in the exchange rate between the U.S. dollar and the Local Currency. While this approach is designed to minimize the impact of currency fluctuations on Series returns, it does not necessarily eliminate the Series exposure to the Local Currency.  Currency hedges are sometimes subject to imperfect matching between the Currency Hedge Contract and the currencies that the contract intends to hedge, and there can be no assurance that the Currency Hedge Contract will be effective. The return of the Currency Hedge Contract will not perfectly offset the actual fluctuations between the Local Currency and the U.S.

Currency Swap Risk. In order to hedge currency risk, the Series enters into a Currency Hedge Contract. The Currency Hedge Contract is subject to market risk, risk of default by the other party to the transaction, known as “counterparty risk,” and risk of imperfect correlation between profit or loss on the Currency Hedge Contract and the underlying currency exchange rate

Foreign Market Risk. Because non-U.S. exchanges such as the London Stock Exchange may be open on days when the Series does not price its Shares, the value of the underlying securities of the ADRs in the Series portfolio may change on days when Shareholders will not be able to purchase or sell the Series Shares, regardless of whether there is an active U.S. market for Shares.

Issuer Concentration Risk. Because the Series only invests in the ADRs of the Company and the Currency Hedge Contract, the Series may be adversely affected by the performance of the Company, subject to increased price volatility and more susceptible to adverse economic, market, political or regulatory occurrences affecting the Company or industry.

Non-Diversification Risk. The Series is non-diversified and holds Portfolio Securities of only one particular issuer. As a result, the Series may have greater volatility than other diversified funds

Management Risk. The Series is subject to the risk that the Manager’s investment management strategy, the implementation of which is subject to a number of constraints, may not produce the intended results.

Pharmaceutical Industry Risk. The profitability of companies in the pharmaceutical industry is highly dependent on the development,procurement and marketing of drugs and the development, protection and exploitation of intellectual property rights and other proprietary information. These companies may be significantly affected by such events as the expiration of patents or the loss of, or the inability to enforce, intellectual property rights.

New Series Risk. As of the date of this prospectus, the Series has no operating history and currently has fewer assets than larger funds. Like other new funds, large inflows and outflows may impact the Series market exposure for limited periods of time. This impact maybe positive or negative, depending on the direction of market movement during the period affected.

Distributor: Foreside Fund Services, LLC